MG
XFOR icon

Michael Gelband’s X4 Pharmaceuticals XFOR Stock Holding History

Michael Gelband’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,703
Closed -$60.7K – 2141
2026
Q1 		$60.7K Sell
14,703
-64,369
-81% -$241K ﹤0.01% 1456
2025
Q4 		$316K Buy
+79,072
New +$287K ﹤0.01% 1299
2021
Q3 		– Sell
-1,896
Closed -$370K – 2709
2021
Q2 		$370K Buy
+1,896
New +$477K ﹤0.01% 1610

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Michael Gelband's XFOR Position: Q2 2026 in Review

Michael Gelband sold out of X4 Pharmaceuticals (XFOR) in Q2 2026, closing a stake of 14,703 shares — an estimated $60.7K sold.

Michael Gelband first reported a position in XFOR in Q2 2021 and held it in 3 quarters. The position peaked at $370K in Q2 2021. 88 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Michael Gelband reported no remaining X4 Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 14,703 X4 Pharmaceuticals shares in Q2 2026, an estimated $60.7K.
  • Michael Gelband first reported a position in X4 Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Michael Gelband's X4 Pharmaceuticals position peaked at $370K in Q2 2021.
  • 88 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.